11 hrs ago
Covance Given "Neutral" Rating at SunTrust
's stock had its "neutral" rating reaffirmed by stock analysts at SunTrust in a report issued on Thursday.
18 hrs ago
Covance finds early phase work rebound in Q2 as central labs growth continues
The season of quarterly reports is in full swing, with CRO Covance seeing its income and revenue rise in Q2 compared with the same quarter last year due to stronger-than expected early phase development and central labs work.
Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639...
Covance Inc. today reported results for its second quarter ended June 30, 2014. Net revenue was $639 million, representing 8.0% growth from the second quarter of 2013.
Covance Receives Average Recommendation of "Buy" from Brokerages
Shares of Covance have received a consensus recommendation of "Buy" from the sixteen analysts that are covering the stock, StockRatingsNetwork.com reports .
Covance Receives Average Rating of "Buy" from Brokerages
Covance has been given a consensus rating of "Buy" by the sixteen analysts that are presently covering the stock, Analyst Ratings News reports .
Covance Inc. Increases Its Medical And Scientific Leadership With Two Senior-Level Appointments
Dr. Robert Wasserman named Vice President and Global Therapeutic Area Head, Oncology and Dr. Rogelio Mosqueda-Garcia named Global Vice President, Early Clinical Services within Medical & Scientific Affairs Princeton, N.J. - July 9, 2014 - Covance today announced two key additions to its clinical development services scientific leadership team with ... (more)
"Covance, Inc. - Mergers & Acquisitions (M&A), Partnerships &...
The Covance, Inc. Mergers & Acquisitions , Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions , divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Covance, Inc. since January 2007.